MedTrace Logo

A Study to Evaluate a New Tablet Formulation of Lu AG06466 in Healthy Participants

NCT05028673 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 16

Last updated 2022-01-21

No results posted yet for this study

Summary

The main goal of this trial is to learn how a new tablet formulation of Lu AG06466 behaves in the body. Researchers will compare the new tablet formulation to the capsule formulation that is currently being tested in other clinical trials. They will measure the levels of the drug in the bloodstream for up to 3 days after participants take either the tablet or the capsule formulation. They will also look at whether the tablet formulation behaves differently when it is taken with and without food.

Conditions

  • Healthy

Interventions

DRUG

Lu AG06466 Capsule

Hard capsule

DRUG

Lu AG06466 Tablet

Film-coated tablet

DRUG

Antacid

Oral suspension

Sponsors & Collaborators

  • H. Lundbeck A/S

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-08-23
Primary Completion
2021-12-29
Completion
2021-12-29

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05028673 on ClinicalTrials.gov